Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker
AstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market.
The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient’s cells to fight the disease.
About Author
More Stories
Millions of Australian workers to get an above-inflation pay rise as minimum wage lifts by 3.5%
High-rise, high expectations: is Casablanca’s finance hub a model for African development?
Amazon ‘testing humanoid robots to deliver packages’